KR890005035A - 벤조일아미노페녹시부탄산 유도체와 그의 제조방법 및 이를 포함하는 제약조성물 - Google Patents
벤조일아미노페녹시부탄산 유도체와 그의 제조방법 및 이를 포함하는 제약조성물 Download PDFInfo
- Publication number
- KR890005035A KR890005035A KR1019880005407A KR880005407A KR890005035A KR 890005035 A KR890005035 A KR 890005035A KR 1019880005407 A KR1019880005407 A KR 1019880005407A KR 880005407 A KR880005407 A KR 880005407A KR 890005035 A KR890005035 A KR 890005035A
- Authority
- KR
- South Korea
- Prior art keywords
- phenoxy
- butanoic acid
- dimethylbenzoylamino
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- APFWWFLTHWSHQP-UHFFFAOYSA-N 2-benzamido-2-phenoxybutanoic acid Chemical class C=1C=CC=CC=1OC(C(O)=O)(CC)NC(=O)C1=CC=CC=C1 APFWWFLTHWSHQP-UHFFFAOYSA-N 0.000 title claims 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 231100000252 nontoxic Toxicity 0.000 claims 11
- 230000003000 nontoxic effect Effects 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- -1 4-methylbenzyloxy Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000004631 alopecia areata Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- IROUWMGSFAAJBL-UHFFFAOYSA-N 4-[2-[(2,3-dimethyl-4-phenylmethoxybenzoyl)amino]phenoxy]butanoic acid Chemical compound CC1=C(C)C(C(=O)NC=2C(=CC=CC=2)OCCCC(O)=O)=CC=C1OCC1=CC=CC=C1 IROUWMGSFAAJBL-UHFFFAOYSA-N 0.000 claims 1
- WBKYUWWBTBMFOI-UHFFFAOYSA-N 4-[2-[[2,3-dichloro-4-[[4-(2-methylpropyl)phenyl]methoxy]benzoyl]amino]phenoxy]butanoic acid Chemical compound C1=CC(CC(C)C)=CC=C1COC(C(=C1Cl)Cl)=CC=C1C(=O)NC1=CC=CC=C1OCCCC(O)=O WBKYUWWBTBMFOI-UHFFFAOYSA-N 0.000 claims 1
- YBYDJZQIWRPGEC-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-(2-phenylethoxy)benzoyl]amino]phenoxy]butanoic acid Chemical compound CC1=C(C)C(C(=O)NC=2C(=CC=CC=2)OCCCC(O)=O)=CC=C1OCCC1=CC=CC=C1 YBYDJZQIWRPGEC-UHFFFAOYSA-N 0.000 claims 1
- HSUWJXRWDVJTEJ-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-(3-phenylpropoxy)benzoyl]amino]phenoxy]butanoic acid Chemical compound CC1=C(C)C(C(=O)NC=2C(=CC=CC=2)OCCCC(O)=O)=CC=C1OCCCC1=CC=CC=C1 HSUWJXRWDVJTEJ-UHFFFAOYSA-N 0.000 claims 1
- HSUBRKPHTNLCID-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-(4-phenylbutoxy)benzoyl]amino]phenoxy]butanoic acid Chemical compound CC1=C(C)C(C(=O)NC=2C(=CC=CC=2)OCCCC(O)=O)=CC=C1OCCCCC1=CC=CC=C1 HSUBRKPHTNLCID-UHFFFAOYSA-N 0.000 claims 1
- CCTVYLZLJRFZMI-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-[(2-methylphenyl)methoxy]benzoyl]amino]phenoxy]butanoic acid Chemical compound CC1=CC=CC=C1COC(C(=C1C)C)=CC=C1C(=O)NC1=CC=CC=C1OCCCC(O)=O CCTVYLZLJRFZMI-UHFFFAOYSA-N 0.000 claims 1
- WKDAYWYZFZSJTK-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-[(3-methylphenyl)methoxy]benzoyl]amino]phenoxy]butanoic acid Chemical compound CC1=CC=CC(COC=2C(=C(C)C(C(=O)NC=3C(=CC=CC=3)OCCCC(O)=O)=CC=2)C)=C1 WKDAYWYZFZSJTK-UHFFFAOYSA-N 0.000 claims 1
- CORHGGXXKPMPRX-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-[(4-propan-2-ylphenyl)methoxy]benzoyl]amino]phenoxy]butanoic acid Chemical compound C1=CC(C(C)C)=CC=C1COC(C(=C1C)C)=CC=C1C(=O)NC1=CC=CC=C1OCCCC(O)=O CORHGGXXKPMPRX-UHFFFAOYSA-N 0.000 claims 1
- LDYXLXHJGHDIJY-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-[(4-propylphenyl)methoxy]benzoyl]amino]phenoxy]butanoic acid Chemical compound C1=CC(CCC)=CC=C1COC(C(=C1C)C)=CC=C1C(=O)NC1=CC=CC=C1OCCCC(O)=O LDYXLXHJGHDIJY-UHFFFAOYSA-N 0.000 claims 1
- JLNGLXUZMMQWNV-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-[(4-propylphenyl)methoxy]benzoyl]amino]phenyl]sulfanylbutanoic acid Chemical compound C1=CC(CCC)=CC=C1COC(C(=C1C)C)=CC=C1C(=O)NC1=CC=CC=C1SCCCC(O)=O JLNGLXUZMMQWNV-UHFFFAOYSA-N 0.000 claims 1
- YVLGXKSBAJTEIC-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-[(4-propylphenyl)methoxy]benzoyl]amino]phenyl]sulfinylbutanoic acid Chemical compound C1=CC(CCC)=CC=C1COC(C(=C1C)C)=CC=C1C(=O)NC1=CC=CC=C1S(=O)CCCC(O)=O YVLGXKSBAJTEIC-UHFFFAOYSA-N 0.000 claims 1
- XWNSOVPLENXWNU-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-[1-[4-(2-methylpropyl)phenyl]ethoxy]benzoyl]amino]phenoxy]butanoic acid Chemical compound C1=CC(CC(C)C)=CC=C1C(C)OC(C(=C1C)C)=CC=C1C(=O)NC1=CC=CC=C1OCCCC(O)=O XWNSOVPLENXWNU-UHFFFAOYSA-N 0.000 claims 1
- NPCMXYRZGBTWSW-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-[[4-(2-methylpropyl)phenyl]methoxy]benzoyl]amino]phenoxy]butanoic acid Chemical compound C1=CC(CC(C)C)=CC=C1COC(C(=C1C)C)=CC=C1C(=O)NC1=CC=CC=C1OCCCC(O)=O NPCMXYRZGBTWSW-UHFFFAOYSA-N 0.000 claims 1
- QVWLDVIHWPLDQZ-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-4-[[4-(trifluoromethyl)phenyl]methylamino]benzoyl]amino]phenoxy]butanoic acid Chemical compound CC1=C(C)C(C(=O)NC=2C(=CC=CC=2)OCCCC(O)=O)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 QVWLDVIHWPLDQZ-UHFFFAOYSA-N 0.000 claims 1
- HNSVVWPUPFONQP-UHFFFAOYSA-N 4-[2-[[4-[(4-chlorophenyl)methoxy]-2,3-dimethylbenzoyl]amino]phenoxy]butanoic acid Chemical compound CC1=C(C)C(C(=O)NC=2C(=CC=CC=2)OCCCC(O)=O)=CC=C1OCC1=CC=C(Cl)C=C1 HNSVVWPUPFONQP-UHFFFAOYSA-N 0.000 claims 1
- NWLWGFMIWYALFB-UHFFFAOYSA-N 4-[2-[[4-[(4-ethylphenyl)methoxy]-2,3-dimethylbenzoyl]amino]phenoxy]butanoic acid Chemical compound C1=CC(CC)=CC=C1COC(C(=C1C)C)=CC=C1C(=O)NC1=CC=CC=C1OCCCC(O)=O NWLWGFMIWYALFB-UHFFFAOYSA-N 0.000 claims 1
- GJBKCBPLNGAZCI-UHFFFAOYSA-N 4-[2-[[4-[[4-(2-methylpropyl)phenyl]methoxy]-5,6,7,8-tetrahydronaphthalene-1-carbonyl]amino]phenyl]sulfanylbutanoic acid Chemical compound C1=CC(CC(C)C)=CC=C1COC(C=1CCCCC=11)=CC=C1C(=O)NC1=CC=CC=C1SCCCC(O)=O GJBKCBPLNGAZCI-UHFFFAOYSA-N 0.000 claims 1
- BLMYRHVGGQQXSR-UHFFFAOYSA-N 4-[2-[[4-[[4-(2-methylpropyl)phenyl]methoxy]naphthalene-1-carbonyl]amino]phenoxy]butanoic acid Chemical compound C1=CC(CC(C)C)=CC=C1COC(C1=CC=CC=C11)=CC=C1C(=O)NC1=CC=CC=C1OCCCC(O)=O BLMYRHVGGQQXSR-UHFFFAOYSA-N 0.000 claims 1
- KGEMNKCQFKXRFF-UHFFFAOYSA-N 4-[2-[[4-[[4-(cyclobutylmethyl)phenyl]methoxy]-2,3-dimethylbenzoyl]amino]phenoxy]butanoic acid Chemical compound CC1=C(C)C(C(=O)NC=2C(=CC=CC=2)OCCCC(O)=O)=CC=C1OCC(C=C1)=CC=C1CC1CCC1 KGEMNKCQFKXRFF-UHFFFAOYSA-N 0.000 claims 1
- TYZLEETZCKODMZ-UHFFFAOYSA-N 4-[2-[[4-[bis(4-propylphenyl)methylsulfanyl]-2,3-dimethylbenzoyl]amino]phenoxy]butanoic acid Chemical compound C1=CC(CCC)=CC=C1C(C=1C=CC(CCC)=CC=1)SC(C(=C1C)C)=CC=C1C(=O)NC1=CC=CC=C1OCCCC(O)=O TYZLEETZCKODMZ-UHFFFAOYSA-N 0.000 claims 1
- CKNAKWJZBCMQQJ-UHFFFAOYSA-N 4-[2-[[4-[bis[(4-propylphenyl)methyl]amino]-2,3-dimethylbenzoyl]amino]phenoxy]butanoic acid Chemical compound C1=CC(CCC)=CC=C1CN(C=1C(=C(C)C(C(=O)NC=2C(=CC=CC=2)OCCCC(O)=O)=CC=1)C)CC1=CC=C(CCC)C=C1 CKNAKWJZBCMQQJ-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (16)
- 하기 일반식의 벤조일아미노페녹시부탄산 유도체 또는 그의 비독성염 :[상기식에서 R1는 수소원자 또는 탄소원자 1 내지 4개의 알킬기를 나타내고, A는 산소원자, 황원자 또는 설피닐(SO)기를 나타내고, 두개의 R1기는 동시에 메틸기 또는 염소원자를 나타내거나 또는 이들이 붙어있는 벤젠고리의 탄소원자와 함께 시클로펜탄, 시클로헥산 또는 벤젠고리를 형성하고, R2는 하기 일반식(i),(ii) 또는 (iii)의 기를 나타내고 ;(상기식에서 B는 산소원자, 황원자 또는 일반식 NR"기(상기식에서 R"은 수소원자 또는 탄소원자 1 내지 4개의 알킬기를 나타낸다)를 나타내고 ; R3, R4, R5, R6, R7및 R8은 독립적으로 수소원자, 탄소원자 1 내지 4개의 알킬기, 할로겐원자, 트리플루오로메틸기 또는 시클로부틸메틸기를 나타내고, m은 0 또는 1을 나타내고, n은 1 내지 5의 정수를 나타내고, 같거나 다를 수 있는 R9와 R10은 각각 수소원자, 탄소원자 1 내지 5개의 알킬기 또는 하기 일반식의 기를 나타내며 ;(상기식에서 R12, R13, R14및 R15는 독립적으로, 수소원자, 탄소원자 1 내지 4개의 알킬기, 할로겐원자, 트리플루오로메틸기 또는 시클로부틸메틸기를 나타내고 1은 1 내지 4의 정수를 나타낸다)단, 이때 R9와 R10은 동시에 수소원자를 나타내지 않는다)].
- 제1항에 있어서, R2가 일반식(i)의 기인 화합물.
- 제2항에 있어서, 두개의 R1기 모두가 메틸기인 화합물.
- 제1항 또는 제3항에 있어서, 4-[2-(4-벤질톡시-2,3-디메틸벤조일아미노)페녹시]부탄산, 4-[2-[4-(2-메틸벤질톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(3-메틸벤질톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[(4-메틸벤질톡시)-2,3-디메틸벤조이아미노]페녹시]부탄산, 4-[2-[4-(2,6-디메틸벤질톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(4-에틸벤질톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(4-프로필벤질톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(4-이소프로필벤질톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(4-이소부틸벤질톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(4-클로로벤질톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(4-시클로부틸메틸벤질톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(2-페닐에톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(3-페닐프로폭시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(4-페닐부톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(5-페닐펜틸톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-[1-(4-이소부틸페닐)에톡시]-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-(4-프로필벤질톡시)-2,3-디메틸벤조일아미노]-페닐티오]부탄산, 4-[2-[4-[1-(4-이소부틸페닐)에톡시-2,3-디메틸벤조일아미노]피닐티오]부탄산, 4-[2-[4-(4-프로필벤질톡시)-2,3-디메틸벤조일아미노]페닐설피닐]부탄산, 또는 4-[2-[4-[N-(4-트리플루오로메틸페닐메틸)아미노]-2,3-디메틸벤조일아미노]페녹시]부탄산, 또는 그의 비-독성염인 화합물.
- 제2항에 있어서, 두개의 R1기가 염소원자 또는 그들이 벤젠고리의 탄소원자와 함께 시클로펜탄, 시클로헥산 또는 벤젠고리를 나타내는 화합물.
- 제1항 또는 제5항에 있어서, 4-[2-[4-(4-이소부틸벤질톡시)-2,3-디클로로벤조일아미노]페녹시]부탄산, 4-[2-(7-(4-이소부틸벤질톡시)인단-4-카르보닐아미노]페녹시]부탄산, 4-[2-[4-(4-이소부틸벤질톡시)-5,6,7,-테트라히드로나프탈렌-1-카르보닐아미노]페녹시]부탄산, 4-[2-[4-(4-이소부틸벤질톡시)나프탈렌-1-카르보닐아미노]페녹시]부탄산, 또는 4-[2-[4-(4-이소부틸벤질톡시)-5,6,7,8-테트라히드로나프탈렌-1-카르보닐아미노]페닐티오]부탄산, 또는 그의 비-독성염인 화합물.
- 제1항에 있어서, R2가 일반식(ii)의 기인 화합물.
- 제1항 또는 제7항에 있어서, 4-[2-[4-비스(4-프로필페닐)메톡시]-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-(4-디페닐메톡시)-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-[비스(4-프로필페닐)메틸아미노]-2,3-디메틸벤조일아미노]페녹시]부탄산, 또는 4-[2-[4-[비스(4-프로필페닐)메틸티오]-2,3-디메틸벤조일아미노]페녹시]부탄산, 또는 그의 비-독성염인 화합물.
- 제1항에 있어서, R2가 일반식(iii)의 기인 화합물.
- 제1항 또는 제9항에 있어서, 4-[2-[4-[N,N-비스(4-프로필페닐메틸)아미노]-2,3-디메틸벤조일아미노]페녹시]부탄산, 4-[2-[4-[N,N-비스(4-트리플루오로메틸페닐메틸)아미노]-2,3-디메틸벤조일아미노]페녹시]부탄산 또는 4-[2-[4-[N-메틸-N-(5,6,7,8-테트라히드로나프트-1-일)아미노메틸]-2,3-디메틸벤조일아미노]페녹시]부탄산 또는 그의 비-독성염인 화합물.
- 하기 (A),(B),(C)단계를 포함하는, 제1항에 따른 벤조일아미노페녹시부탄산 유도체의 제조방법 : (A) 하기 일반식(Ia)의 화합물을 제조하기 위해 하기 일반식(II)의 카르복실산 또는 그의 활성 유도체를 하기 일반식(III)의 아민과 반응시키고 ;상기식에서, A'는 산소원자 또는 황원자를 나타내고, R은 하기 일반식의 기를 나타내고 :(상기식에서 각종 기호는 제1항에서 정의한 바와같다.) B'는 산소원자 또는 황원자를 나타내고, 그밖의 다른 기호는 제1항에서 정의한 바와같다.(상기식에서 B'는 앞에서 정의한 바와같고 R과 R'는 제1항에서 정의한 바와같다)(상기식에서 R"는 탄소원자 1 내지 4개의 알킬기를 나타내고 A'는 앞에서 정의한 바와같다) (B) 하기 일반식(Ib)의 화합물을 제조하기 위해서, 하기 일반식(Ib')의 화합물을 산화시켜 -S-기를 -S(=O)-기로 전환시키고 ;(상기식에서 R', R1과 R2는 제1항에서 정의한 바와같다)(상기식에서 R', R1과 R2는 제1항에서 정의한 바와같다) (C) 하기 일반식(Ic)의 화합물을 제조하기 위해서, 하기 일반식(IV)의 화합물과 하기 일반식(V),(VI),(VII) 및/또는 (VIII)(IX)의 화합물을 반응시키거나 또는 하기 일반식(X)의 화합물과 하기 일반식( )의 화합물을 반응시키고[(상기식에서 RA는 하기 일반식 (i'),(ii')또는 (iii')의 기를 나타내며 ;(상기식에서 모든 기호는 제1항에서 정의한 바와같다). R1과 R'는 제1항에서 정의한 바와같고 A'는 앞에서 정의한 바와같다](상기식에서 R1은 제1항에서 정의한 바와같고 A'와 R"는 앞에서 정의한 바와같다) ;(상기식에서 X1,X2,X3,X4및 X5는 각각 할로겐원자, 토실기 또는 메실기를 나타내고 그밖의 다른 기호는 제1항에서 정의한 바와같다)(상기식에서 X6는 할로겐원자, 토실기 또는 메실기를 나타내고, R1은 제1항에서 정의한 바와같고 A'와 R"는 앞에서 정의한 바와같다)(상기식에서 R9와 R10은 제1항에서 정의한 바와같다.) ; 원한다면, 이렇게 하여 얻은 일반식(I)의 화합물을 가수분해하여 -COOR'기(여기에서 R'은 탄소원자 1 내지 4개를 갖는 알킬기를 나타낸다.)를 COOH기로 전환시키고/거나 R'가 수소원자를 나타내는 일반식(I)화합물을 그의 비독성염으로 전환시킨다.
- 제1항에 따른 벤조일아미노페녹시부탄산 유도체 또는 그의 비독성염과 함께 제약학적으로 허용가능한 담체 또는 코우팅을 포함하는 제약학적 조성물.
- 약제제조에 이용하기 위한 제1항에 따른 벤조일아미노페녹시부탄산 유도체 또는 그의 비독성 염.
- 원형탈모증, 좌창 또는 전립선 비대의 치료약제 제조에 이용하기 위한 제1항에 따른 벤조일아미노페녹시부탄산 유도체 또는 그의 비독성 염.
- 일반식(I)의 벤조일아미노페녹시부탄산 유도체 또는 그의 비독성염을 포함하는 코스메틱 조성물.
- 좌창 또는 원형탈모증의 치료에 일반식(I)의 벤조일아미노페녹시부탄산 유도체 또는 그의 비-독성염을 코스메틱제품으로 이용하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP112618 | 1987-05-11 | ||
| JP62-112618 | 1987-05-11 | ||
| JP11261887 | 1987-05-11 | ||
| JP62-231194 | 1987-09-17 | ||
| JP231194 | 1987-09-17 | ||
| JP23119487 | 1987-09-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR890005035A true KR890005035A (ko) | 1989-05-11 |
| KR970006891B1 KR970006891B1 (ko) | 1997-04-30 |
Family
ID=26451734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019880005407A Expired - Lifetime KR970006891B1 (ko) | 1987-05-11 | 1988-05-09 | 벤조일아미노페녹시부탄산 유도체와 그의 제조방법 및 이를 포함하는 제약 조성물 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4980372A (ko) |
| EP (1) | EP0291245B1 (ko) |
| JP (1) | JPH0657685B2 (ko) |
| KR (1) | KR970006891B1 (ko) |
| DE (1) | DE3872937T2 (ko) |
| ES (1) | ES2051843T3 (ko) |
| GR (1) | GR3005835T3 (ko) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0725725B2 (ja) * | 1987-07-23 | 1995-03-22 | 保土谷化学工業株式会社 | ベンズアミド誘導体 |
| US5591892A (en) * | 1990-02-12 | 1997-01-07 | Center For Innovative Technology | Allosteric modifiers of hemoglobin |
| WO1992013828A1 (en) * | 1991-02-08 | 1992-08-20 | Yamanouchi Pharmaceutical Co., Ltd. | Novel benzanilide derivative or salt thereof |
| NZ241979A (en) * | 1991-03-20 | 1996-01-26 | Merck & Co Inc | Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker |
| EP0525885A1 (en) * | 1991-07-29 | 1993-02-03 | Merck & Co. Inc. | New sulphur containing nonsteroidal drugs as 5-alpha reductase inhibitors |
| CA2074537A1 (en) * | 1991-07-29 | 1993-01-30 | Bruce E. Witzel | Catechol type non-steroidal drugs as 5-alpha reductase inhibitors |
| CA2074539A1 (en) * | 1991-07-29 | 1993-01-30 | Bruce E. Witzel | Non-steroidal agents as 5-alpha reductase inhibitors |
| US5250539A (en) * | 1991-08-21 | 1993-10-05 | Eli Lilly And Company | Hexahydrobenzo[f]quinolinones |
| WO1993024442A1 (en) * | 1992-05-29 | 1993-12-09 | Yamanouchi Pharmaceutical Co., Ltd. | Medicine containing benzoic acid derivative and novel benzoic acid derivative |
| JPH0641038A (ja) * | 1992-07-17 | 1994-02-15 | Mitsubishi Kasei Corp | カルボン酸誘導体 |
| WO1999007357A1 (fr) * | 1997-08-08 | 1999-02-18 | Ono Pharmaceutical Co., Ltd. | REGULATEURS DE TYPE η DE RECEPTEUR ACTIVE D'AGENT DE PROLIFERATION DE PEROXYSOME |
| US6670358B2 (en) * | 2000-05-16 | 2003-12-30 | Cephalon, Inc. | Substituted thioacetamides |
| US6492396B2 (en) | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| WO2003020311A1 (fr) * | 2001-08-28 | 2003-03-13 | Fujisawa Pharmaceutical Co., Ltd. | Remedes contre les maladies de la peau |
| EP1581472A2 (en) * | 2002-12-20 | 2005-10-05 | MIGENIX Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| EP1586560A1 (en) * | 2004-04-13 | 2005-10-19 | Cephalon, Inc. | Thio-substituted arylmethanesulfinyl derivatives |
| US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
| AR074760A1 (es) * | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| AU2018238138A1 (en) | 2017-03-21 | 2019-10-17 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1077936A (en) * | 1964-09-08 | 1967-08-02 | Smith & Nephew | Substituted benzanilides |
| GB1088295A (en) * | 1965-07-10 | 1967-10-25 | Smith & Nephew | Derivatives of alkanoic acids and methods for their preparation |
| US3549689A (en) * | 1967-05-23 | 1970-12-22 | Sandoz Ag | Phenoxy-alkanoic acids |
| CA1261835A (en) * | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
| NO174506B (no) * | 1984-10-30 | 1994-02-07 | Usv Pharma Corp | Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser |
-
1988
- 1988-05-06 US US07/191,193 patent/US4980372A/en not_active Expired - Fee Related
- 1988-05-06 DE DE8888304120T patent/DE3872937T2/de not_active Expired - Fee Related
- 1988-05-06 EP EP88304120A patent/EP0291245B1/en not_active Expired - Lifetime
- 1988-05-06 ES ES88304120T patent/ES2051843T3/es not_active Expired - Lifetime
- 1988-05-09 KR KR1019880005407A patent/KR970006891B1/ko not_active Expired - Lifetime
- 1988-05-11 JP JP63112386A patent/JPH0657685B2/ja not_active Expired - Fee Related
-
1992
- 1992-09-30 GR GR920402169T patent/GR3005835T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0291245A3 (en) | 1989-10-18 |
| DE3872937T2 (de) | 1993-01-21 |
| EP0291245A2 (en) | 1988-11-17 |
| KR970006891B1 (ko) | 1997-04-30 |
| DE3872937D1 (de) | 1992-08-27 |
| JPH01156950A (ja) | 1989-06-20 |
| JPH0657685B2 (ja) | 1994-08-03 |
| EP0291245B1 (en) | 1992-07-22 |
| US4980372A (en) | 1990-12-25 |
| GR3005835T3 (ko) | 1993-06-07 |
| ES2051843T3 (es) | 1994-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR890005035A (ko) | 벤조일아미노페녹시부탄산 유도체와 그의 제조방법 및 이를 포함하는 제약조성물 | |
| AU7137591A (en) | New derivatives having naphthalene structure, process for preparing these and pharmaceutical compositions containing them | |
| KR910019612A (ko) | 옥살릴아미노산 유도체, 이의 제조방법 및 프롤린 하이드록실라제 억제용 약제로서의 이의 용도 | |
| DE3271269D1 (en) | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same | |
| ES499870A0 (es) | Un procedimiento para la preparacion de derivados de indano | |
| DE60011462D1 (de) | Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung | |
| KR890000407A (ko) | 신규 "벤조일아미노페녹시부탄산 유도체" 및 그의 제조방법 | |
| KR840007596A (ko) | 유기인 유도체의염의 제조방법 | |
| RU94026094A (ru) | Применение феналкиламинов | |
| FI933719A0 (fi) | 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol | |
| KR910004597A (ko) | 1-(피리디닐아미노)-2-피롤리디논, 이의 제조방법 및 약제로서의 이의 용도 | |
| KR910006309A (ko) | 인지질 및 인지질 유도체를 유효 성분으로 하는 항비루스성 약제 | |
| DK601683D0 (da) | Dialkylaminoalkoxybenzylalkoholderivater | |
| KR910004598A (ko) | 2,3-디하이드로-1-(피리디닐아미노)-인돌, 이의 제조방법 및 약제로서 이의 용도 | |
| CA2231025A1 (fr) | Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MXPA01007705A (es) | Derivado de benzamida y medicamento que lo contiene. | |
| KR920006346A (ko) | 3-(1h-인다졸-3-일)-4-피리딘아민, 이의 제조방법, 이의 제조를 위한 중간체 및 약제로서의 이의 용도 | |
| ATE43594T1 (de) | 3-alkoxy-2-(n-pyrrolidino)-n-pyridyl-n-furyl(od r thienyl)-methyl-propylamine, ihre herstellung und diese enthaltende pharmazeutische mittel. | |
| RU96120092A (ru) | Новые производные пиперазина и способы их получения и содержащие их композиции | |
| KR910015547A (ko) | 이미다졸 화합물, 이의 제조방법, 이들 화합물을 함유하는 약제 및 중간체 | |
| SE8206230D0 (sv) | Novel cyclic imines, their preparation and pharmaceutical compositions containing the same | |
| ATE56705T1 (de) | Piperidinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate. | |
| KR920002531A (ko) | 스페르구알린 관련 신규화합물 및 그 제조방법 | |
| JPS55139346A (en) | Preparation of bis(8-guanidinooctyl)amine acetic acid salt | |
| KR910007875A (ko) | 도파민 길항제로서의 벤질피롤리딘 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19880509 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19930508 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19880509 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19960531 Patent event code: PE09021S01D |
|
| G160 | Decision to publish patent application | ||
| PG1605 | Publication of application before grant of patent |
Comment text: Decision on Publication of Application Patent event code: PG16051S01I Patent event date: 19970331 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19970711 |
|
| NORF | Unpaid initial registration fee | ||
| PC1904 | Unpaid initial registration fee |